Florida 2023 Regular Session

Florida House Bill H0963 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3	HB 963 2023
4	4
5	5
6	6
7	7	CODING: Words stricken are deletions; words underlined are additions.
8	8	hb0963-00
9	9	Page 1 of 4
10	10	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
11	11
12	12
13	13
14	14	A bill to be entitled 1
15	15	An act relating to HIV infection prevention drugs; 2
16	16	creating s. 465.1861, F.S.; defining terms; 3
17	17	authorizing licensed pharmacists to screen for HIV 4
18	18	exposure and order and dispense HIV infection 5
19	19	prevention drugs in accordance with a certain written 6
20	20	supervisory protocol or statewide drug therapy 7
21	21	protocol; requiring pharmacists to be certified by the 8
22	22	Board of Pharmacy before ordering and dispensing HIV 9
23	23	infection prevention drugs; requiring the board, in 10
24	24	consultation with the Board of Medicine and the Board 11
25	25	of Osteopathic Medicine, to adopt rules for such 12
26	26	certification; specifying minimum requirements for the 13
27	27	certification; requiring the board, in consultation 14
28	28	with the Board of Medicine, the Board of Osteopathic 15
29	29	Medicine, and the Department of Health, to develop a 16
30	30	certain statewide drug therapy protocol; providing 17
31	31	requirements for development of the protocol; 18
32	32	requiring the board to adopt rules, including 19
33	33	specified rules; providing an effective date. 20
34	34	21
35	35	Be It Enacted by the Legislature of the State of Florida: 22
36	36	23
37	37	Section 1. Section 465.1861, Florida Statutes, is created 24
38	38	to read: 25
39	39
40	40	HB 963 2023
41	41
42	42
43	43
44	44	CODING: Words stricken are deletions; words underlined are additions.
45	45	hb0963-00
46	46	Page 2 of 4
47	47	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
48	48
49	49
50	50
51	51	465.1861 Ordering and dispensing HIV infection prevention 26
52	52	drugs.— 27
53	53	(1) As used in this section, the term: 28
54	54	(a) "HIV" means the human immunodeficiency virus. 29
55	55	(b) "HIV infection prevention drug" means preexposure 30
56	56	prophylaxis, postexposure prophylaxis, and any other drug 31
57	57	approved by the United States Food and Drug Administration for 32
58	58	the prevention of HIV infection. 33
59	59	(c) "Postexposure prophylaxis" means a drug or drug 34
60	60	combination that meets the clinical eligibility recommendations 35
61	61	of the United States Centers for Disease Control and Prevention 36
62	62	guidelines for antiretroviral treatment following potential 37
63	63	exposure to HIV. 38
64	64	(d) "Preexposure prophylaxis" means a drug or drug 39
65	65	combination that meets the clinical eligibility recommendations 40
66	66	of the United States Centers for Disease Control and Prevention 41
67	67	guidelines for antiretroviral treatment for the prevention of 42
68	68	HIV transmission. 43
69	69	(2) A pharmacist may screen for HIV exposure and order and 44
70	70	dispense HIV infection prevention drugs in accordance with a 45
71	71	written protocol between the pharmacist and a supervising 46
72	72	physician or a statewide drug therapy proto col developed 47
73	73	pursuant to subsection (4). 48
74	74	(3) Before ordering or dispensing HIV infection prevention 49
75	75	drugs under this section, a pharmacist must be certified by the 50
76	76
77	77	HB 963 2023
78	78
79	79
80	80
81	81	CODING: Words stricken are deletions; words underlined are additions.
82	82	hb0963-00
83	83	Page 3 of 4
84	84	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
85	85
86	86
87	87
88	88	board, according to the rules adopted by the board, in 51
89	89	consultation with the Board of Med icine and the Board of 52
90	90	Osteopathic Medicine. To be certified, a pharmacist must, at a 53
91	91	minimum, meet all of the following criteria: 54
92	92	(a) Hold an active and unencumbered license to practice 55
93	93	pharmacy under this chapter. 56
94	94	(b) Be engaged in the active practic e of pharmacy. 57
95	95	(c) Have earned a doctorate of pharmacy degree or have 58
96	96	completed at least 5 years of experience as a licensed 59
97	97	pharmacist. 60
98	98	(d) Maintain at least $250,000 of liability coverage. A 61
99	99	pharmacist who maintains liability coverage pursuant to s. 62
100	100	465.1865 or s. 465.1895 satisfies this requirement. 63
101	101	(e) Have completed a course approved by the board, in 64
102	102	consultation with the Board of Medicine and the Board of 65
103	103	Osteopathic Medicine, which includes, at a minimum, instruction 66
104	104	on all of the following: 67
105	105	1. Performance of patient assessments. 68
106	106	2. Point-of-care testing procedures. 69
107	107	3. Safe and effective treatment of HIV exposure with HIV 70
108	108	infection prevention drugs. 71
109	109	4. Identification of contraindications. 72
110	110	(4) The board, in consultation with the Board o f Medicine, 73
111	111	the Board of Osteopathic Medicine, and the department, shall 74
112	112	develop a statewide drug therapy protocol for pharmacists to 75
113	113
114	114	HB 963 2023
115	115
116	116
117	117
118	118	CODING: Words stricken are deletions; words underlined are additions.
119	119	hb0963-00
120	120	Page 4 of 4
121	121	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
122	122
123	123
124	124
125	125	test or screen for HIV exposure and order and dispense HIV 76
126	126	infection prevention drugs. In development of the statewide dru g 77
127	127	therapy protocol, the board must consider, at a minimum, all of 78
128	128	the following: 79
129	129	(a) Physician referrals. 80
130	130	(b) Lab testing, including prescribing HIV preexposure and 81
131	131	postexposure screening tests. 82
132	132	(c) Appropriate referrals consistent with guidelines of 83
133	133	the United States Centers for Disease Control and Prevention. 84
134	134	(d) Counseling consistent with guidelines of the United 85
135	135	States Centers for Disease Control and Prevention. 86
136	136	(e) Patient follow-up care and counseling. 87
137	137	(5) The board shall adopt rules to im plement this section, 88
138	138	including rules that establish protocols for ordering and 89
139	139	dispensing HIV infection prevention drugs. 90
140	140	Section 2. This act shall take effect July 1, 2023. 91